this Gliflozines (or SGLT2 inhibitors) is an anti-diabetic drug that arrived on the market a few years ago. In this category we find Dapagliflozine (Forxiga*, Astrazeneca), Canagliflozine (Invokana*, Janssen) and Empagliflozine (Jardiance*, Boehringer Ingelheim/Lilly). Unlike other diabetes treatments, these drugs increase elimination blood sugar via urine – taking oral.
A new class of promising drugs
There French Diabetes Federation (FFD) explains these “In the case of reference to oral antidiabetic agents (e.g. metformin, sulfonamides), the molecule is directed to the management of the treatment of type 2 diabetes associated with hygienic measures that are no longer adequate or tolerable and do not ensure glycemic balance, but More specifically to prevent balancing of many many many many many many numbers. Diabetic complications (especially Canaglifozine or cardiovascular renal)“.
Effectively regulate blood sugar, Gliflozines can also treat Insufficient heart It has been approved for this prescription in Europe for four years. But until then, this Treatment Based on clinical studies only. The new scientific publication is based on data collected directly from patients, in other words, profiles of more people than clinical studies. Goal: Confirm (or not) result previous.
Heart failure: encouraging research
from Statens Serum Institute from Copenhagen, Karolinska Institutet Photographs from the universities of Stockholm and Copenhagen were taken from more than 20,000 patients, more than 45, over three years.heart failure. The results of their work are published in british medical journal Confirmation that SGLT2 inhibitors significantly reduce risk of mortality Insufficient heart Reduced ejection fraction. “””SGLT-2 inhibitor use associated with risk of mortality 25% lowerwhich confirms their effectiveness in current clinical practiceThey draw conclusions.
